James Brugarolas
Overview
Explore the profile of James Brugarolas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
6754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kapur P, Zhong H, Christie A, Xu H, Cai Q, Araj E, et al.
J Natl Cancer Inst
. 2025 Mar;
PMID: 40065697
The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. This study evaluated two large independent cohorts for differences in tumor biology between patients who developed metastases...
2.
Hein D, Christie A, Holcomb M, Xie B, Jain A, Vento J, et al.
medRxiv
. 2025 Feb;
PMID: 39990557
Background: Extracting structured data from free-text medical records is laborious and error-prone. Traditional rule-based and early neural network methods often struggle with domain complexity and require extensive tuning. Large language...
3.
Wang L, Guer M, Puri D, Liu F, Dhanji S, Meagher M, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941733
Objectives: The incidence of renal cell carcinoma (RCC) has been rising, largely due to increased incidental detection from widespread imaging. Although synchronous distant metastasis (SM) with a primary renal tumor...
4.
Liao C, Hu L, Jia L, Zhou J, Wang T, Kim K, et al.
Nat Commun
. 2025 Feb;
16(1):1543.
PMID: 39934163
Clear cell renal cell carcinoma (ccRCC), a metabolic disease originating from renal proximal convoluted tubule (PCT) epithelial cells, remains incompletely understood in terms of its initiating signaling events. Here, we...
5.
Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, et al.
Eur Urol
. 2025 Jan;
PMID: 39855942
Neoadjuvant systemic treatment strategies have improved outcomes in several solid tumour types. This success has not yet been replicated in renal cell carcinoma (RCC). A consensus and international collaboration are...
6.
Chen M, Wang K, Kapur P, Brugarolas J, Hannan R, Wang J
ArXiv
. 2024 Dec;
PMID: 39713797
Purpose: A reliable and comprehensive cancer prognosis model for clear cell renal cell carcinoma (ccRCC) could better assist in personalizing treatment. In this work, we developed a multi-modal ensemble model...
7.
Bischoff M, Shamsaei B, Yang J, Secic D, Vemuri B, Reisz J, et al.
Cancer Discov
. 2024 Oct;
15(2):401-426.
PMID: 39476412
The work establishes a requirement for glucose-dependent coordination between energy production and redox homeostasis, which is fundamental for the survival of cancer cells that accumulate Cu and contributes to tumor...
8.
Hamidi O, Miljanic M, Tumyan G, Christie A, Mirfakhraee S, Ali S, et al.
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335112
Background: Adrenal metastases are often treated with stereotactic ablative radiation (SAbR). We aimed to assess the incidence, timing, and factors associated with the development of primary adrenal insufficiency (PAI) following...
9.
Gunenc D, Issa W, Gerald T, Zhou Q, Zhang S, Ibezue I, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(5):102177.
PMID: 39218752
Background: Immunotherapy (IO) has improved outcomes for patients with metastatic renal cell carcinoma (mRCC). However, the timing of surgical intervention for cytoreductive nephrectomy (CN) is still controversial for this group...
10.
Lee J, Dan T, Zhang H, Cheng Y, Rehfeld F, Brugarolas J, et al.
bioRxiv
. 2024 Aug;
PMID: 39091767
Cancer cells frequently upregulate ribosome production to support tumorigenesis. While small nucleolar RNAs (snoRNAs) are critical for ribosome biogenesis, the roles of other classes of noncoding RNAs in this process...